Trial Watch No. 13
Allogeneic CAR T Crosses Three Categories at Once
The first half of July 2026 delivers a categorical breakthrough. Allogeneic CAR T reaches Phase 2 across three fundamentally different disease categories in the same two-week window; AstraZeneca's AZD4045 (BCMA in relapsed or refractory Multiple Myeloma), Fate Therapeutics' FT819 (iPSC derived CAR T in refractory SLE with lupus nephritis), and BrainChild Bio's BCB-276 (locoregional B7-H3 in diffuse intrinsic pontine glioma). KRAS G12D reaches Phase 3 for the first time, and oral GLP-1 competition widens to eight sponsors.
Summary Layer
The first half of July 2026 delivers a categorical breakthrough. Allogeneic CAR T reaches Phase 2 across three fundamentally different disease categories in the same two-week window; AstraZeneca's AZD4045 (BCMA in relapsed or refractory Multiple Myeloma), Fate Therapeutics' FT819 (iPSC derived CAR T in refractory SLE with lupus nephritis), and BrainChild Bio's BCB-276 (locoregional B7-H3 in diffuse intrinsic pontine glioma). Off the shelf CAR T is no longer a future promise; three sponsors, three modalities, three indications, one operational moment.
Mega obesity Phase 3 escalates again. Structure Therapeutics' ACCOMPLISH-2 (aleniglipron) enrolls 3,600 patients; the largest single molecule obesity Phase 3 registered by a small cap biotech to date. AstraZeneca opens Eluminate-1 (elecoglipron with or without dapagliflozin, 800 patients, 149 sites); AZ's Phase 3 entry into oral GLP-1 territory. The global oral obesity field now spans eight sponsors.
First line Multiple Myeloma fragments further. PrECOG Belantamab Mafodotin vs. Daratumumab in newly diagnosed Multiple Myeloma and Leeds's iFIT (UK-MRA Myeloma XVIII) quintuplet; teclistamab plus talquetamab plus daratumumab plus lenalidomide plus dexamethasone at 1,226 patients; mark the third and fourth Phase 3s attacking daratumumab's first line position across four consecutive editions. 15 high signal trials across oncology, cardiometabolic, immunology, neurology, and advanced modalities.
Therapeutic Areas Covered
Oncology
5 trialsPetosemtamab plus Chemotherapy vs. Cetuximab plus Chemotherapy in First Line Left Sided Metastatic Colorectal Cancer
Genmab's EGFRxLGR5 bispecific goes head to head with cetuximab in 1L mCRC
Timeline
Start: July 2026. Primary completion: July 2029.
Mechanism
Petosemtamab is Genmab's EGFRxLGR5 bispecific antibody, run head to head against cetuximab in RAS/BRAF wild type left sided colorectal cancer in the first line setting.
Why It Matters
Cetuximab has dominated EGFR blockade in metastatic colorectal cancer for two decades. Petosemtamab's dual EGFR and LGR5 targeting is designed to overcome cetuximab resistance and improve depth of response. A 960-patient direct head to head is Genmab's most operationally committed oncology bet; continuing the 2026 pattern of sponsors running next-gen assets against approved class leaders instead of placebo.
Verified sources
iFIT (UK MRA Myeloma XVIII); Fitness Adapted Immunotherapy in Newly Diagnosed Multiple Myeloma
Leeds-led UK academic quintuplet stacks teclistamab plus talquetamab onto Dara-Rd in 1L MM
Timeline
Start: July 2026. Primary completion: June 2033.
Mechanism
Fitness-adapted immunotherapy platform in newly diagnosed transplant ineligible Multiple Myeloma. Compares daratumumab plus lenalidomide plus dexamethasone against regimens incorporating teclistamab (BCMAxCD3 bispecific T cell engager) and talquetamab (GPRC5DxCD3 bispecific T cell engager).
Why It Matters
Third and fourth BCMA/GPRC5D bispecifics moving into first line Multiple Myeloma across three consecutive editions (after Regeneron Linvoseltamab in Edition 11 and Heidelberg Teclistamab quadruplet in Edition 12). At 1,226 patients, iFIT is the largest Multiple Myeloma Phase 3 challenging the daratumumab standard. UK-MRA is a top-tier academic myeloma consortium; independent readouts carry weight beyond sponsor-run trials.
Belantamab Mafodotin vs. Daratumumab With VRd in Newly Diagnosed Multiple Myeloma
PrECOG runs the first ADC vs. CD38 antibody head to head in 1L MM
Timeline
Start: July 2026. Primary completion: November 2031.
Mechanism
Head-to-head Phase 3 comparing belantamab mafodotin (GSK's BCMA-directed ADC with an MMAF payload) versus daratumumab hyaluronidase, each combined with bortezomib plus lenalidomide plus dexamethasone in newly diagnosed Multiple Myeloma.
Why It Matters
First direct Phase 3 head to head between an ADC (Blenrep) and a CD38 antibody (Darzalex) in first line Multiple Myeloma. Blenrep was withdrawn by the FDA in 2022 over DREAMM-3 confirmatory failure, then reapproved in 2025 based on DREAMM-8. This trial is the definitive test of whether BCMA ADC can displace CD38 antibody as the anchoring first line partner. Continues Editions 11 to 12's parallel BCMA bispecific pushes into first line Multiple Myeloma.
Verified sources
GFH375 vs. Docetaxel in KRAS G12D Positive Advanced Non Small Cell Lung Cancer
Genfleet delivers the first Phase 3 of any KRAS G12D inhibitor
Timeline
Start: July 15, 2026. Primary completion: June 2030.
Mechanism
GFH375 is Genfleet's oral KRAS G12D inhibitor, run against docetaxel in patients with locally advanced or metastatic non small cell lung cancer harboring KRAS G12D mutations who have failed prior standard therapy.
Why It Matters
First Phase 3 of any KRAS G12D-targeted therapy; KRAS G12D is 4x more common than KRAS G12C but has been undrugged until recently. Genfleet is the first sponsor to reach Phase 3 in the G12D franchise, with Mirati (BMS), Amgen, Revolution Medicines, and Xencor all in earlier development. If GFH375 wins, KRAS G12D becomes a $3B+ addressable market and unlocks pancreatic plus colorectal indication expansion.
Verified sources
Rinatabart Sesutecan With or Without Bevacizumab vs. Platinum Chemotherapy in Second Line Platinum Sensitive Ovarian Cancer
Genmab's Rina-S expands from platinum-resistant into platinum-sensitive ovarian cancer
Timeline
Start: July 2026. Primary completion: December 2029.
Mechanism
Rina-S (FRα directed ADC with exatecan payload) moves from Edition 11's platinum resistant ovarian Phase 3 into the earlier second line platinum sensitive setting, tested against carboplatin, gemcitabine, paclitaxel or PLD combinations with or without bevacizumab.
Why It Matters
Genmab is running Rina-S in two parallel Phase 3s covering both platinum sensitive and platinum resistant ovarian cancer within three editions; an aggressive lifecycle strategy for the FRα ADC class. If both readouts hit, Rina-S captures the entire ovarian cancer second line and later market. Mirvetuximab (AbbVie) faces class-internal competition on two fronts.
Verified sources
Cardiometabolic
4 trialsFinerenone in HFpEF After Transcatheter Aortic Valve Implantation
2,832-patient TAVI-specific finerenone Phase 3 extends Bayer's HFpEF franchise
Timeline
Start: July 1, 2026. Primary completion: December 2029.
Mechanism
Finerenone (Bayer's non-steroidal MRA, approved in HFmrEF and HFpEF via FINEARTS-HF) tested against placebo in HFpEF patients undergoing transcatheter aortic valve implantation.
Why It Matters
2,832 patient TAVI specific finerenone Phase 3; the largest interventional cardiology Phase 3 in this window. Extends finerenone's HFpEF footprint into the growing TAVI population (over 150K procedures annually in the US alone). If positive, finerenone becomes standard after TAVI care and expands Bayer's franchise into the interventional cardiology setting.
PREEMPT; Rosuvastatin plus Colchicine for Premature Atherosclerosis Prevention
Duke opens the first primary-prevention Phase 3 combining LDL lowering and anti-inflammation
Timeline
Start: July 1, 2026. Primary completion: July 2031.
Mechanism
Randomizes patients with multiple CAD risk factors and evidence of premature atherosclerosis to rosuvastatin 20 mg plus colchicine 0.5 mg daily vs. placebo. Tests whether combined LDL lowering plus anti inflammation prevents progression.
Why It Matters
Third major colchicine cardiovascular Phase 3 across recent editions (Edition 11 PHRI ICH, and Duke PREEMPT this edition), consolidating colchicine's shift from ACS-only to broader prevention. The combined statin plus colchicine architecture is the first primary prevention Phase 3 of the anti-inflammatory plus LDL-lowering hypothesis at scale.
Verified sources
Eluminate-1; Elecoglipron With or Without Dapagliflozin in Type 2 Diabetes
AstraZeneca's Phase 3 entry into oral GLP-1 territory pre-positions a Farxiga combination
Timeline
Start: July 6, 2026. Primary completion: July 2028.
Mechanism
Elecoglipron is AstraZeneca's oral once-daily GLP-1R agonist, tested as monotherapy and in combination with dapagliflozin (SGLT2 inhibitor, AZ's Farxiga franchise) in Type 2 diabetes. Sister trial Eluminate-5 (2,000 patients, 272 sites) is a combination-only Phase 3 targeting the same window.
Why It Matters
AstraZeneca's Phase 3 entry into oral GLP-1 territory; combined with the Eluminate-5 companion trial (2,000 patients) and prior programs across the metabolic franchise, AZ is pre-positioning a Farxiga plus Elecoglipron fixed dose combination. Oral GLP-1 field is now Novo (oral semaglutide), Lilly (orforglipron), Structure (aleniglipron this edition), Pfizer, Roche and AZ; six sponsors racing.
Verified sources
ACCOMPLISH-2; Aleniglipron for Chronic Weight Management in Obesity and Type 2 Diabetes
Structure Therapeutics' 3,600-patient oral GLP-1 Phase 3 is the largest small-cap obesity commitment to date
Timeline
Start: July 2026. Primary completion: September 2028.
Mechanism
Aleniglipron (GSBR-1290) is Structure Therapeutics' oral once-daily small-molecule GLP-1R agonist. ACCOMPLISH-2 tests multiple maintenance doses vs. placebo in adults with obesity plus Type 2 diabetes. Sister trial ACCOMPLISH-1 (3,600 patients) covers obesity without diabetes.
Why It Matters
Structure Therapeutics is the highest-conviction small cap obesity biotech to reach Phase 3. Combined ACCOMPLISH-1 plus ACCOMPLISH-2 program at 7,200 patients across two Phase 3s represents mega-program commitment from a mid cap. Aleniglipron's oral-small-molecule design competes head to head with orforglipron (Lilly) and oral semaglutide (Novo). Structure IPO'd in 2023; ACCOMPLISH readouts will determine its independence versus acquisition trajectory.
Verified sources
Immunology
2 trialsEMERGE; Claseprubart (DNTH103) in Generalized Myasthenia Gravis
Dianthus tests the first classical-pathway-selective complement mAb in gMG Phase 3
Timeline
Start: July 2026. Primary completion: December 2028.
Mechanism
Claseprubart is Dianthus's selective anti-C1s complement monoclonal antibody, tested in generalized myasthenia gravis. Targets the classical complement pathway upstream, in contrast to argenx efgartigimod (FcRn) and UCB rozanolixizumab (FcRn).
Why It Matters
New mechanism entering the increasingly crowded gMG field. FcRn dominates today (Vyvgart, Rystiggo); C5 antagonism was tried (eculizumab, ravulizumab); Claseprubart's upstream C1s inhibition is the first classical-pathway-selective approach to Phase 3 in gMG. If positive, adds a fourth mechanistic option to gMG treatment and opens Dianthus into adjacent complement-mediated autoimmune indications.
Verified sources
Rezpegaldesleukin (NKTR-358) Monotherapy in Moderate-to-Severe Atopic Dermatitis (12 years and older)
Nektar tests the first Treg-expanding IL-2 pathway therapy in atopic dermatitis Phase 3
Timeline
Start: July 2026. Primary completion: May 2028.
Mechanism
Rezpegaldesleukin is a PEGylated IL-2 receptor selective agonist designed to preferentially expand regulatory T cells (Tregs); restoring immune tolerance rather than blocking a specific cytokine. Contrast with anti-IL-13 (lebrikizumab), anti-IL-31 (nemolizumab), and anti-IL-4/13 (dupilumab).
Why It Matters
First Phase 3 of a Treg-expanding IL-2 pathway therapy in atopic dermatitis; a fundamentally different mechanism from current Th2 cytokine antagonists. Nektar previously partnered with Lilly on this asset before regaining rights in 2023. If positive, opens Tregitope-based immunomodulation as a category and validates the Treg-expansion thesis Nektar has been building for a decade. Dupilumab (Sanofi/Regeneron) and lebrikizumab (Lilly) face a new mechanism category.
Verified sources
Neurology
1 trialSAR448851 in Early Alzheimer's Disease With Open Label Extension
Sanofi's most prominent CNS Phase 2 entry in years enters early AD
Timeline
Start: July 1, 2026. Primary completion: July 2029.
Mechanism
SAR448851 is Sanofi's investigational Alzheimer's disease asset (target not yet disclosed publicly). 48-week treatment period plus open-label extension in early AD patients.
Why It Matters
Sanofi's most prominent CNS Phase 2 entry in years. Alzheimer's is currently dominated by anti-amyloid antibodies (lecanemab, donanemab). Sanofi's late arrival to Alzheimer's with a Phase 2 asset; while the tau field (Edition 12 Aisen ATP platform) is expanding; signals a differentiated mechanism approach. Watch for target disclosure at first major medical meeting.
Verified sources
Advanced Modalities
3 trialsAZD4045; Allogeneic BCMA CAR T in Relapsed or Refractory Multiple Myeloma
AstraZeneca's first solo off-the-shelf CAR T from a top-10 pharma enters clinic
Timeline
Start: July 9, 2026. Primary completion: October 2029.
Mechanism
AZD4045 is AstraZeneca's allogeneic, off the shelf CAR T targeting BCMA in relapsed or refractory Multiple Myeloma. Modular Phase 1/2 design tests dosing and combination with daratumumab and aldesleukin (IL-2). First allogeneic BCMA CAR T from a top-10 pharma sponsor entering clinic; novel modality on a validated target.
Why It Matters
AstraZeneca's first solo allogeneic CAR T entry. Combined with Fate Therapeutics FT819 (iPSC CAR T in SLE with lupus nephritis, this edition), BrainChild BCB-276 (B7-H3 CAR T in diffuse intrinsic pontine glioma, this edition), and prior editions' allogeneic and universal CAR T programs, off the shelf CAR T is now a five sponsor field at Phase 1/2 or beyond. Autologous CAR T (Kymriah, Yescarta, Breyanzi, Carvykti, Abecma) faces a modality-succession threat if allogeneic durability approaches autologous levels.
Verified sources
RECLAIM-LN; FT819 iPSC Derived CD19 CAR T in Refractory SLE With Lupus Nephritis
Fate's iPSC-derived CAR T reaches Phase 2 in autoimmune disease
Timeline
Start: July 1, 2026. Primary completion: July 2029.
Mechanism
FT819 is Fate Therapeutics' iPSC-derived (fully allogeneic / off the shelf) CD19 CAR T. RECLAIM-LN tests FT819 in refractory moderate-to-severe SLE with WHO Class III/IV lupus nephritis.
Why It Matters
First iPSC-derived CAR T Phase 2 in autoimmune disease. Combined with the autoimmune CAR T map across Editions 8 to 12 (Breakfree-SSc, Descartes-08, mosunetuzumab, CABA-201 in MS, BMS-986353 in ITP/AIHA, C-CAR168 in LN), FT819 becomes the sixth mechanism in the autoimmune B-cell modality stack. The iPSC delivery; theoretically infinitely scalable and lower-cost than autologous CAR T; is the class-defining differentiator if durability holds.
Verified sources
BCB-276; B7-H3 Specific CAR T Locoregional Immunotherapy in Diffuse Intrinsic Pontine Glioma
BrainChild's pivotal locoregional CAR T targets one of oncology's hardest pediatric indications
Timeline
Start: July 2026. Primary completion: October 2028.
Mechanism
BCB-276 is a B7-H3-specific CAR T administered via locoregional (intracranial / CNS) delivery in diffuse intrinsic pontine glioma; one of the most aggressive pediatric CNS tumors. Locoregional delivery addresses the two structural barriers to solid-tumor CAR T: systemic toxicity and blood-brain barrier penetration.
Why It Matters
BrainChild Bio spun out of Seattle Children's B7-H3 CAR T program that showed prior single center response signals in diffuse intrinsic pontine glioma. Pivotal Phase 2 at 75 patients is the definitive test; diffuse intrinsic pontine glioma has median survival of 9 to 12 months and no effective therapies. Combined with T-MAXIMUM's MT027 UCAR T in GBM (Edition 12), CNS-delivered CAR T is now a two-sponsor category in some of oncology's hardest indications.
Verified sources
Signal Convergence
Allogeneic and off-the-shelf CAR T reaches Phase 2 across three categories at once
AstraZeneca AZD4045 (BCMA in Multiple Myeloma), Fate FT819 (iPSC CAR T in SLE with lupus nephritis), BrainChild BCB-276 (B7-H3 in diffuse intrinsic pontine glioma). Three sponsors, three modalities, three indications, one window. The autologous CAR T era faces its clearest modality-succession threat since Kymriah's 2017 approval.
Oral GLP-1 obesity competition reaches eight sponsors
Structure Therapeutics ACCOMPLISH-2 (aleniglipron, 3,600 patients) and AstraZeneca Eluminate-1 / Eluminate-5 (elecoglipron, 800 plus 2,000 patients) join Novo, Lilly, Pfizer, Roche, Boehringer Ingelheim, and Hengrui. Oral obesity is now the most crowded Phase 3 field in cardiometabolic medicine.
First line Multiple Myeloma fragments further
PrECOG Belantamab Mafodotin vs. Daratumumab plus iFIT (teclistamab plus talquetamab quintuplet at 1,226 patients). Third and fourth Phase 3s attacking daratumumab's first line standard across four consecutive editions. The daratumumab era in newly diagnosed Multiple Myeloma is under siege from ADC, BCMA bispecific, and GPRC5D bispecific frameworks simultaneously.
KRAS G12D reaches Phase 3 for the first time
Genfleet GFH375 vs. docetaxel in KRAS G12D positive non small cell lung cancer; the first Phase 3 of any KRAS G12D-targeted therapy. G12D is 4x more common than G12C and remained undrugged until this program. If GFH375 wins, KRAS G12D becomes a $3B+ addressable market.
Cardiovascular anti-inflammation reaches primary prevention scale
Duke PREEMPT (rosuvastatin plus colchicine in premature atherosclerosis, 1,500 patients) opens the first primary prevention Phase 3 combining LDL lowering and anti inflammation. Third major colchicine cardiovascular Phase 3 across three editions. Colchicine's expansion from ACS-only to broader prevention is now definitive.
Underlying truth: every major modality is now in mid-to-late stage expansion across multiple sponsors. The bottleneck has moved from "does the modality work" to "which sponsor secures the first three indications first"; and the operational scale keeps escalating (2,832-patient after TAVI HFpEF, 3,600-patient obesity, 1,226-patient Multiple Myeloma).
On Verification
Every trial in this edition is anchored to three deterministic, verifiable sources sitting inline under each entry: the trial's ClinicalTrials.gov record, its WHO ICTRP cross-listing (deterministic URL pattern), and the sponsor's evergreen clinical trials search portal where one exists. Dated press-release URLs are intentionally not embedded inline because they 404 over time. All 15 trials in this edition have start dates verified to fall within July 1 to July 15, 2026, and none repeat from Editions 1 to 12.
About Trial Watch
Trial Watch is Kitsa's twice-monthly U.S. clinical intelligence briefing. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.